logo
Toyota Might Bring a New Truck to the U.S. That Would Defy All the Odds

Toyota Might Bring a New Truck to the U.S. That Would Defy All the Odds

Yahoo11 hours ago
Currently, just two trucks exist in the compact pickup market — Toyota is prepared to get in on the action.
Led by historically low fuel prices, regulatory loopholes and changing consumer preferences, a variety of factors have contributed to the ever-growing size of vehicles in the United States.
Ultimately, though, there's no getting around the fact that it's spawned something of an arms race wherein drivers are determined to be behind the wheel of the biggest thing on the road — often more out of a feeling of self-preservation than any real need for the size.
However, some automakers (Ford and Hyundai) have heeded the call to downsize their offerings and demonstrated a clear demand for compact pickups. With the Maverick and the Santa Cruz being the only two trucks of their kind on the US market, it seems that Toyota now has its eye on a piece of the pie.
Compact competition
Since introducing the Maverick in late 2021, Ford has improved on the model's sales performance with each passing year. So, even though some 74,370 buyers lined up for a Maverick in the first full year that it was on the market, that number climbed to 94,058 units in 2023 and then again to 131,142 units in 2024.
And here's the thing — despite a tumultuous first half of 2025 plagued by tariffs and other political uncertainties, Ford has managed to keep the momentum going. With 98,078 Mavericks moved to date, the Blue Oval has posted an 8.9 percent improvement compared to 2024.
Now, it's worth noting that Hyundai hasn't enjoyed the same kind of success in the compact truck segment with the Santa Cruz. Though the brand managed to grow its pickup sales to 36,675 units in 2023, that number fell to 32,033 in 2024. Hyundai is also down 20 percent on the year at just 16,532 trucks sold.
In any case, Ford is showing that an established brand reputation in the compact truck segment can make for big gains, while Hyundai is having better luck with its efforts to attract new EV buyers. Given that Toyota's data projects that it could sell 100,000 to 150,000 compact trucks per year in the U.S. alone, there's still plenty of untapped potential for an automaker known for bestsellers like the mid-size Tacoma and the full-size Tundra.
Toyota intentions
Toyota recognizes as much. In a recent interview with Bloomberg, Mark Templin, COO of Toyota America, stated the brand was 'looking at it' when discussing the possibility of entering the small truck market.
By contrast, Cooper Ericksen, head of planning and strategy for Toyota North America, proved far more forthcoming in his talks with MotorTrend. Along with confirming that 'decisions have been made' and that 'we're committed to it,' he also revealed that the pickup will be a unibody truck based on the existing TNGA platform.
Moreover, in speaking to the outlet, Ericksen acknowledged that 'full-size trucks and midsize trucks have really gotten expensive.' While the added cost is warranted for those who demand the capability, not everyone wants something that can take them into parts unknown.
Consider the Slate EV, for instance. In just two weeks, the electric truck managed to rack up more than 100,000 reservations, marketed for affordability and customization potential rather than typical pickup considerations like payload or towing capacity. Regardless of the powertrain, it's clear that 'small' is in style.
A matter of time
In speaking to MotorTrend, Ericksen also confirmed that 'it's not a matter of 'if,' at this point' but rather 'how to make it work.'
At the time, Toyota was primarily focused on bolstering its all-electric lineup, and the development of such vehicles was proving to be far too taxing to justify work on a compact truck simultaneously. After all, the brand had previously announced a plan to introduce 24 new or updated models through a revised mixed-energy initiative.
However, circumstances have since changed. From the phasing out of federal tax incentives to the increasingly bipartisan anti-EV sentiments, electric cars aren't likely to be at the top of Toyota's agenda. If the brand wants to capitalize on the success of Ford's Maverick, it's only a matter of time before its own small truck hits the market.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time24 minutes ago

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Gartner cuts annual revenue forecast on slower research demand
Gartner cuts annual revenue forecast on slower research demand

Yahoo

time24 minutes ago

  • Yahoo

Gartner cuts annual revenue forecast on slower research demand

(Reuters) -Gartner cut its annual revenue forecast on Tuesday, anticipating slower demand for its biggest research unit as businesses dialed back on spending in an uncertain economy. Shares of the company fell 11% in premarket trading. Gartner now expects $100 million less from its insights unit in 2025, which led to the company to now forecast total revenue of at least $6.46 billion this year. The company, however, expects annual profit of at least $11.75 per share, up 5 cents from its prior forecast, due to favorable foreign exchange rates. Businesses have been streamlining costs to counter ongoing inflation and subdued customer spending, leading to softer demand for Gartner's services. Analysts have said that advancement in automation and AI, which enables clients to improve performance with tools developed in-house, has created uncertainty for consulting services firms like Gartner. However, the insights segment, which accounts for more than half of total sales, reported a 4.3% rise in revenue in the second quarter. This boosted the company's total revenue to $1.69 billion for the quarter ended June 30, compared with analysts' average estimate of $1.67 billion, according to data compiled by LSEG. Gartner's consulting segment recorded a nearly 9% rise in quarterly revenue to $155.6 million. On an adjusted basis, the company earned $3.53 per share, beating estimates of $3.30. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Coinbase premium just dropped a huge signal for Bitcoin's price to hit $130,000
Coinbase premium just dropped a huge signal for Bitcoin's price to hit $130,000

Yahoo

time24 minutes ago

  • Yahoo

Coinbase premium just dropped a huge signal for Bitcoin's price to hit $130,000

US investors are quietly piling into Bitcoin after a wobble that saw its price decline 4% in the last week amid a $9 billion selloff and late-month geopolitical jitters. The bubbling buying spree is visible in the Coinbase Bitcoin premium gap on CryptoQuant, a market data platform. The metric tracks the difference in the Bitcoin price on Coinbase Pro and other exchanges, including Binance. It has flipped positive, signalling that US demand is rebounding, further fuelling analysts' bullishness on Bitcoin's long-term price prospects. 'Bitcoin to trade between $130,000 and $150,000 by year-end, assuming continued [exchange-traded fund] inflows and a stable macro environment, [but] much will hinge on upcoming Federal Reserve decisions, particularly the anticipated rate cut in September,' analysts at TeraHash, a Bitcoin yield protocol, told DL News. An interest rate slash by the Federal Reserve is seen as rocket fuel for Bitcoin because lower interest rate environments favour assets like crypto and stocks. And traders are already pricing in an 88% chance of a September rate cut, according to the CME's FedWatch tool. James Butterfill, head of research at CoinShares, a crypto investment firm, said he expects the Federal Reserve to pivot sharply dovish, a policy shift that favours growth over inflation control, usually by reducing interest rates for cheaper borrowing. 'The Fed is on the back foot and overly concerned with transitory inflation issues and is likely to do a knee-jerk rate cut; it's debatable as to whether this will be September or later, though,' Butterfill said. To be sure, some analysts say Bitcoin has lost some momentum in the short term following its recent price slump. Analysts at Bitfinex, a crypto exchange, say they expect Bitcoin to consolidate between $114,000 and $116,000 unless something triggers new market moves. Bitcoin traded just above $114,000 on Tuesday, down 7% from its all-time high of $122,838 achieved on July 14. Crypto market movers Bitcoin has gained 0.4% over the past 24 hours and is trading at $114,747. Ethereum is up 3.1% in the same period to $3,671. What we're reading Aave's $4.7bn Ethena exposure risks setting off 'liquidity crunch,' adviser says — DL News CurveDAO Member Proposes Cutting L2 Deployments — Unchained Can PumpFun be dethroned? — Milk Road Crypto Donors Sent $45 Million to Trump's Super PAC: Report — Unchained Why Mode Network's investor deposits dropped 99% in one year — DL News Osato Avan-Nomayo is our Nigeria-based DeFi correspondent. He covers DeFi and tech. Got a tip? Please contact him at osato@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store